[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639680":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":51,"collaborators":20,"id":53,"slug":20,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":72,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TQ05105 tablets","OTHER","TQ05105 tablets combined with rabeprazole sodium enteric-coated tablets, 14 days as a treatment cycle.",[13,14],"Drug: TQ05105 tablets","Drug: Rabeprazole sodium enteric-coated tablets",[16,21],{"type":17,"name":9,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","TQ05105 tablets are Janus kinase (JAK) inhibitors.",[9],null,{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":20},"Rabeprazole sodium enteric-coated tablets","Rabeprazole sodium enteric-coated tablets.",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Guoping Yang, Doctor","CONTACT","0731-89918665","ygp9880@163.com",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},"Xiaocong Zuo, Doctor","13808466377","zuoxc08@126.com",[36],{"facility":37,"status":20,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"The Third Xiangya Hospital, Central South University","Changsha","Hunan","410013","China","CN",{"type":44,"coordinates":45},"Point",[46,47],112.97087,28.19874,{"lat":47,"lon":46},[50],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"type":52,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100639680",false,"NCT07608666","Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets","A Single-center, Open-label, Single-dose, Fixed-dose Regimen, Self-controlled Phase I Clinical Trial to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the pH-dependent Pharmacokinetics of TQ05105 Tablets","Inclusion Criteria:\n\n* Signed informed consent prior to the study, fully understood the study content, procedures and potential adverse reactions; able to complete the study per protocol requirements.\n* The participant (including partner) agrees not to plan pregnancy, sperm donation or egg donation from screening until 6 months after the last study drug administration, and is willing to use effective contraception.\n* Healthy male and female participants aged 18-45 years (inclusive).\n* Male body weight ≥ 50.0 kg; female body weight ≥ 45.0 kg.BMI = weight (kg)\u002Fheight² (m²), range 18.0-28.0 kg\u002Fm² (inclusive).\n\nExclusion Criteria:\n\n* Participants with clinically significant abnormalities in vital signs, physical examination, ECG or clinical laboratory tests, and deemed unsuitable for participation by the investigator.\n* Participants with severe or chronic diseases of the circulatory, digestive, respiratory, urinary, nervous, hematologic, endocrine\u002Fmetabolic, neoplastic, immune or psychiatric systems within the past 1 year or currently, or any other disease that may interfere with study results.\n* Platelet count or absolute neutrophil count below the lower limit of the reference range at screening.\n* Any disease increasing bleeding risk, such as hemorrhoids, acute gastritis, gastric or duodenal ulcer.\n* Alanine aminotransferase (ALT) \\> 1.2×ULN, aspartate aminotransferase (AST) \\> 1.2×ULN, alkaline phosphatase (ALP) \\> 1.2×ULN, total bilirubin (TBIL) \\> 1.2×ULN, or any clinically significant abnormality judged by the investigator.\n* Any malignancy within the past 5 years.\n* Any condition that may affect absorption, distribution, metabolism or excretion of study drug (e.g., inability to swallow), or history of gastrointestinal resection that may affect drug disposition.\n* Allergy to rabeprazole, TQ05105 or their excipients; or history of multiple allergies (≥2 substances), including drug allergy, and tendency to develop rash, eczema, urticaria, asthma, etc.\n* Use of any strong or moderate inducers or inhibitors of CYP3A4, CYP2C9 and CYP2C19 within 4 weeks prior to screening.\n* Use of any prescription drugs, over the counter medications, herbal medicines or dietary supplements (e.g., vitamins, calcium supplements) within 4 weeks prior to screening.\n* Use of any acid suppressive therapy within 3 months prior to screening.\n* Participation in any clinical trial involving investigational drugs within 3 months prior to screening or within 5 half lives of the study drug (whichever is longer).\n* Positive results for HIV antibody, hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV) or syphilis antibody.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 90 mL\u002Fmin\u002F1.73m² at screening.\n* Average daily cigarette consumption \\>5 cigarettes within 3 months prior to screening.\n* History of drug abuse within 3 months prior to screening, or positive urine drug screen.\n* Regular alcohol consumption within 3 months prior to screening (≥14 units\u002Fweek; 1 unit = 360 mL beer \u002F 45 mL 40% spirits \u002F 150 mL wine), or positive alcohol breath test.\n* Blood donation or blood loss ≥200 mL, or plasma exchange within 4 weeks prior to screening.\n* Consumption of alcohol (or positive alcohol breath test), grapefruit juice, coffee, tea, cola, chocolate or related food\u002Fbeverage within 72 hours before dosing.\n* Pregnant or breastfeeding female participants, positive serum pregnancy test, or unprotected sexual intercourse within 2 weeks prior to screening for women of childbearing potential.\n* Strenuous exercise (e.g., marathon, weightlifting) within 2 weeks prior to screening.\n* Any other condition deemed unsuitable for participation by the investigator.",true,"ALL","18 Years","45 Years",{"count":64,"type":65},16,"ESTIMATED","INTERVENTIONAL",[68],"PHASE1","Primary objective: To evaluate the effect of rabeprazole on the pharmacokinetics of TQ05105 tablets.\n\nSecondary objective: To assess the safety and tolerability of single oral administration of TQ05105 tablets alone and in combination with rabeprazole in healthy study participants.",[71],"Myelofibrosis","NOT_YET_RECRUITING","2026-05-20",{"date":75,"type":76},"2026-05-27","ACTUAL",{"date":78,"type":65},"2026-06",{"date":80,"type":65},"2026-12",{"name":5,"class":6},1]